Cracking the Code: Innovative Drug Cost Management Strategies That Actually Work
A practical guide for FQHCs and health systems on managing drug costs through specialty pharmacy strategy, biosimilars, smarter utilization, and 340B-aligned infusion models.
Remy Healthcare Team
7 min read · June 12, 2025 · Updated May 17, 2026
Rising drug costs are no longer just a pharmacy problem. For FQHCs, health systems, and safety-net providers, medication inflation affects margin, access, staffing, and long-term service planning. The organizations making progress are not relying on one-off cuts. They are building repeatable systems that reduce waste, improve purchasing discipline, and protect patient care at the same time.
Key Takeaways
- Drug cost management works best when finance, pharmacy, and clinical operations plan together instead of in silos.
- Specialty pharmacy strategy, biosimilars, utilization controls, and 340B-aligned infusion models can all contribute to meaningful savings.
- The strongest programs do not focus only on acquisition cost. They track total value, adherence, reimbursement, and downstream outcomes.
- FQHCs that treat drug cost strategy as an operating capability tend to outperform organizations that treat it as a one-time negotiation project.
Why traditional cost-cutting falls short
Many organizations still respond to rising pharmacy spend with familiar tactics: narrow formularies, manual approval steps, and periodic vendor renegotiations. Those moves can help, but they rarely solve the underlying problem. Drug cost pressure is usually the result of multiple forces working together: expensive biologics, fragmented purchasing, inconsistent adherence, and limited visibility into where margin leaks out of the system.
The better question is not, "How do we cut cost this quarter?" It is, "How do we build a model that consistently improves value per therapy, per patient, and per site?"
What smart drug cost management actually includes
Effective pharmacy cost strategy is usually built from four levers:
- Better channel strategy for high-cost medications
- Smarter utilization management
- Biosimilar adoption where clinically appropriate
- More disciplined use of 340B purchasing and in-house administration
Each of these levers works on its own. The real advantage shows up when they are combined.
Specialty pharmacy strategy: lower waste, tighter coordination
Specialty pharmacy is often treated as a vendor category. In practice, it is an operating model. For organizations managing complex therapies, the right specialty pharmacy approach improves more than purchasing.
It can help with:
- prior authorization workflow
- refill and adherence management
- patient education
- site-of-care coordination
- reimbursement follow-through
When those functions are fragmented, medication spend rises while patient experience gets worse. When they are coordinated, organizations can reduce avoidable delays and improve both utilization and revenue capture.
Specialty pharmacy strategy should be evaluated as a care-delivery system, not just as a contract line item. The operational model often matters as much as the drug price.
Biosimilars are one of the clearest cost opportunities
Biosimilars continue to be one of the most practical ways to reduce spend without lowering quality. For many high-cost therapy classes, the conversation is no longer whether biosimilars are viable. It is how quickly a health system can update workflows, physician education, and formulary behavior to use them well.
The organizations that capture savings typically do three things:
- align clinical leadership on adoption criteria
- educate prescribers and infusion staff early
- monitor conversion and reimbursement performance by therapy line
Without that operating discipline, even a strong biosimilar opportunity can stall.
Utilization management should support care, not slow it down
Prior authorization, step therapy, and therapeutic alternatives can all reduce unnecessary spend. But if those controls are handled manually or inconsistently, they create friction without producing reliable savings.
Strong organizations use utilization management to answer three questions:
- Is this therapy clinically appropriate?
- Is there a lower-cost equivalent with comparable outcomes?
- Is the chosen site of care financially and operationally sound?
That last question is often missed. The same drug can produce very different economics depending on where it is dispensed, administered, and reimbursed.
340B strategy changes the economics when used deliberately
For eligible organizations, 340B is not just a discount mechanism. It is a planning advantage. The highest-performing programs use 340B savings to support broader service-line decisions, especially for infused and provider-administered therapies.
That is why more FQHCs and safety-net providers are evaluating in-house infusion models. Administering high-cost therapies inside a compliant care setting can create a stronger financial structure than routing those therapies entirely off-site.
Done well, this approach can:
- reduce acquisition cost pressure
- improve continuity of care
- keep clinically important treatment on-site
- increase visibility into margin and operational performance
Why infusion strategy belongs in the drug cost conversation
Too many teams separate "pharmacy cost strategy" from "service line growth." In reality, they are often the same conversation.
When high-cost therapies are shifted into an on-site infusion model that aligns with 340B, organizations may be able to improve the economics of treatment delivery while also making care more convenient for patients. That does not mean every provider should build an infusion program. It does mean every eligible organization should assess whether sending those therapies off-site is creating avoidable leakage.
If you are evaluating high-cost therapies only at the purchasing level, you may be missing the larger opportunity. Site of care, reimbursement, and administration model often determine whether savings are real.
What leading organizations do differently
The strongest pharmacy cost programs tend to share the same habits:
- They review drug spend with cross-functional ownership.
- They track both acquisition cost and downstream reimbursement.
- They separate one-time savings from durable operating improvements.
- They use data to identify leakage, not just to report history.
- They connect pharmacy strategy to patient access and care continuity.
This is where many FQHCs can pull ahead. Lean organizations often move faster once the model is clear.
A practical framework for FQHCs and health systems
If you need a starting point, begin with this sequence:
- Audit your top cost-driving therapies by site, payer mix, and margin performance.
- Identify therapies with viable biosimilar or channel alternatives.
- Review where prior auth, inventory, or referral workflows are creating waste.
- Evaluate whether high-cost therapies should stay off-site or move into a 340B-aligned administration model.
- Build a recurring operating review instead of treating cost management as a one-time cleanup.
Think beyond cost-cutting
The goal is not just lower drug spend. The goal is a stronger system: one that helps the organization buy smarter, administer care more efficiently, and protect access for the patients who rely on it most.
Organizations that win here do not simply spend less. They get more value from each therapy decision.
Frequently Asked Questions
- What is the most effective first step for managing rising drug costs?
- Start by identifying the therapies driving the most spend and reviewing them by payer, site of care, reimbursement performance, and utilization pattern. Most organizations need better visibility before they need more tactics.
- Are biosimilars enough on their own to solve drug cost pressure?
- No. Biosimilars are powerful, but they work best as part of a broader system that includes utilization management, specialty pharmacy coordination, and site-of-care strategy.
- How does 340B fit into a drug cost management strategy?
- For eligible providers, 340B can materially improve therapy economics, especially for infused and provider-administered medications. The value is highest when it is tied to compliant operational workflows and thoughtful service-line planning.
- Why does site of care matter in drug cost management?
- Because the same drug can produce very different financial and operational outcomes depending on where it is dispensed, administered, and reimbursed. Site of care is often one of the biggest hidden drivers of total cost.
Want a sharper drug cost strategy?
We help FQHCs and healthcare operators connect 340B, specialty pharmacy, infusion strategy, and operational analytics into one practical financial model.
Talk to Remy
Written by
Remy Healthcare Team
340B & FQHC Specialists
The Remy team advises FQHCs and 340B covered entities on program management, infusion operations, and revenue optimization.
